Nadine Jaschinski

Nadine Jaschinski

Auto-generated profile, based on publicly available information

Nadine Jaschinski

CHIP, Rigshospitalet, University of Copenhagen , Copenhagen

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2022 in AIDS
Verified
Journal Article
Open access
NJNadine Jaschinski
Nadine Jaschinski
LGLauren Greenberg
Lauren Greenberg
BNBastian Neesgaard
Bastian Neesgaard
Jose M MiroJose M Miro
Jose M Miro
KGKatharina Grabmeier-Pfistershammer
Katharina Grabmeier-Pfistershammer
LRLene Ryom
Lene Ryom
Objective: Assessing whether the previously reported association between abacavir (ABC) and cardiovascular disease (CVD) remained amongst contemporarily treated people with HIV. Design: Multinational cohort collaboration. Methods: RESPOND participants were followed from the latest of 1 January 2012 or cohort enrolment until the first of a CVD event (myocardial infarction, stroke, invasive cardiovascular procedure), last follow-up or 31 December 2019. Logistic regression examined the odds of starting ABC by 5-year CVD or chronic kidney disease (CKD) D:A:D risk score. We assessed associations between recent ABC use (use within the past 6 months) and risk of CVD with negative binomial regression models, adjusted for potential confounders. Results: Of 29 340 individuals, 34% recently used ABC. Compared with those at low estimated CVD and CKD risks, the odds of starting ABC were significantly higher among individuals at high CKD risk [odds ratio 1.12 (95% confidence interval = 1.04–1.21)] and significantly lower for individuals at moderate, high or very high CVD risk [0.80 (0.72–0.88), 0.75 (0.64–0.87), 0.71 (0.56–0.90), respectively]. During 6.2 years of median follow-up (interquartile range; 3.87–7.52), there were 748 CVD events (incidence rate 4.7 of 1000 persons-years of follow up (4.3–5.0)]. The adjusted CVD incidence rate ratio was higher for individuals with recent ABC use [1.40 (1.20–1.64)] compared with individuals without, consistent across sensitivity analyses. The association did not differ according to estimated CVD (interaction P = 0.56) or CKD (P = 0.98) risk strata. Conclusion: Within RESPOND's contemporarily treated population, a significant association between CVD incidence and recent ABC use was confirmed and not explained by preferential ABC use in individuals at increased CVD or CKD risk.

15 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
LGLauren Greenberg
Lauren Greenberg
LRLene Ryom
Lene Ryom
EBElzbieta Bakowska
Elzbieta Bakowska
FWFerdinand Wit
Ferdinand Wit
HBHeiner C. Bucher
Heiner C. Bucher
OGon behalf of the RESPOND and D:A:D Study Groups
on behalf of the RESPOND and D:A:D Study Groups
Despite cancer being a leading comorbidity amongst individuals with HIV, there are limited data assessing cancer trends across different antiretroviral therapy (ART)-eras. We calculated age-standardised cancer incidence rates (IRs) from 2006–2021 in two international cohort collaborations (D:A:D and RESPOND). Poisson regression was used to assess temporal trends, adjusted for potential confounders. Amongst 64,937 individuals (31% ART-naïve at baseline) and 490,376 total person-years of follow-up (PYFU), there were 3763 incident cancers (IR 7.7/1000 PYFU [95% CI 7.4, 7.9]): 950 AIDS-defining cancers (ADCs), 2813 non-ADCs, 1677 infection-related cancers, 1372 smoking-related cancers, and 719 BMI-related cancers (groups were not mutually exclusive). Age-standardised IRs for overall cancer remained fairly constant over time (8.22/1000 PYFU [7.52, 8.97] in 2006–2007, 7.54 [6.59, 8.59] in 2020–2021). The incidence of ADCs (3.23 [2.79, 3.72], 0.99 [0.67, 1.42]) and infection-related cancers (4.83 [4.2, 5.41], 2.43 [1.90, 3.05]) decreased over time, whilst the incidence of non-ADCs (4.99 [4.44, 5.58], 6.55 [5.67, 7.53]), smoking-related cancers (2.38 [2.01, 2.79], 3.25 [2.63–3.96]), and BMI-related cancers (1.07 [0.83, 1.37], 1.88 [1.42, 2.44]) increased. Trends were similar after adjusting for demographics, comorbidities, HIV-related factors, and ART use. These results highlight the need for better prevention strategies to reduce the incidence of NADCs, smoking-, and BMI-related cancers.

24 September 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
NJNadine Jaschinski
Nadine Jaschinski
BNBastian Neesgaard
Bastian Neesgaard
FWFerdinand Wit
Ferdinand Wit
MVMarc Van der Valk
Marc Van der Valk
Justyna Dominika KowalskaJustyna Dominika Kowalska
Justyna Dominika Kowalska
FWF Wit
F Wit
Background: Data on uptake of preventive measures for cardiovascular disease (CVD) in people with HIV are limited. Methods: We determined the annual prevalence (2012–2021) of CVD preventive measures use for RESPOND participants with a very high (>10%) estimated D:A:D 10-year CVD risk who were eligible for each specific measure evaluated. We used binomial regression to assess factors associated with each preventative measure uptake. Results: Between 2012 and 2021, the crude proportion of >10% estimated 10-year CVD risk individuals increased from 32.4% (n = 4272) to 52.1% (n = 5298). At the end of follow-up, among very high-risk individuals, 67.4% (1552/2303) with hypertension used antihypertensives, 55.9% (1562/2792) with dyslipidemia lipid-lowering drugs (LLDs), and 7.4% (159/2149) smokers ceased smoking, without significant changes over time. Conversely, a smaller proportion of individuals with diabetes received antidiabetics in later years (2012–2013: 60.3% [388/643] versus 2019–2020: 57.2% [459/803], global P = .0028). Use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs) in those with hypertension or diabetes slightly declined before increasing again (42.1% [864/2052] versus 43.4% [1123/2585], global P = .0009). Individuals with ongoing viremia or intravenous drug use as HIV exposure group were less likely to cease smoking and use LLDs. Men ≥40 years and women ≥50 were more likely to use antihypertensives, ACEIs/ARBs, antidiabetics, and LLDs. The uptake of preventive measures was similar between sexes/genders. Conclusions: The increasing proportion of individuals at very high estimated 10-year CVD risk without a corresponding increase in use of preventive measures calls for greater awareness of CVD risk management for people with HIV attending routine clinical care.